ERK and β-Arrestin Interaction: A Converging Point of Signaling Pathways for Multiple Types of Cell Surface Receptors

Lefkowitz, 2004, Beta-Arrestins: Traffic Cops of Cell Signaling, Curr. Opin. Cell. Biol., 16, 162, 10.1016/j.ceb.2004.01.001 Hupfeld, 2007, Regulation of Receptor Tyrosine Kinase Signaling by GRKs and Beta-Arrestins, Annu. Rev. Physiol., 69, 561, 10.1146/annurev.physiol.69.022405.154626 Akhtar, 2012, Activation of EGFR/ERBB2 via Pathways Involving ERK1/2, P38 MAPK, AKT and FOXO Enhances Recovery of Diabetic Hearts from Ischemia-Reperfusion Injury, PLoS One, 7, e39066, 10.1371/journal.pone.0039066 Lanner, 2010, The Role of FGF/Erk Signaling in Pluripotent Cells, Development, 137, 3351, 10.1242/dev.050146 Hwang, 2004, Interleukin-1 Beta Stimulates IL-8 Expression through MAP Kinase and ROS Signaling in Human Gastric Carcinoma Cells, Oncogene, 23, 6603, 10.1038/sj.onc.1207867 Schrofelbauer, 2011, How Do Pleiotropic Kinase Hubs Mediate Specific Signaling by TNFR Superfamily Members?, Immunol. Rev., 244, 29, 10.1111/j.1600-065X.2011.01060.x Luttrell, 2003, ‘Location, Location, Location’: Activation and Targeting of MAP Kinases by G Protein–Coupled Receptors, J. Mol. Endocrinol., 30, 117, 10.1677/jme.0.0300117 Yao, 2009, The ERK Signaling Cascade: Views from Different Subcellular Compartments, Biofactors, 35, 407, 10.1002/biof.52 Tohgo, 2002, Beta-Arrestin Scaffolding of the ERK Cascade Enhances Cytosolic ERK Activity but Inhibits ERK-Mediated Transcription following Angiotensin AT1a Receptor Stimulation, J. Biol. Chem., 277, 9429, 10.1074/jbc.M106457200 Eishingdrelo, 2013, Minireview: Targeting GPCR Activated ERK Pathways for Drug Discovery, Curr. Chem. Genomics Transl. Med., 7, 9, 10.2174/2213988501307010009 Hammer, 2007, A Novel Enzyme Complementation-Based Assay for Monitoring G-Protein-Coupled Receptor Internalization, FASEB J., 21, 3827, 10.1096/fj.07-8777com Eishingdrelo, 2011, A Cell-Based Protein-Protein Interaction Method Using a Permuted Luciferase Reporter, Curr. Chem. Genomics., 5, 122, 10.2174/1875397301105010122 Violin, 2010, Selectively Engaging Beta-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance, J. Pharmacol. Exp. Ther., 335, 572, 10.1124/jpet.110.173005 Boerrigter, 2010, Cardiorenal Actions of TRV120027, a Novel, Beta-Arrestin–Biased Ligand at the Angiotensin II Type I Receptor, in Healthy and Heart Failure Canines: A Novel Therapeutic Strategy for Acute Heart Failure, J. Card. Fail., 16, S73, 10.1016/j.cardfail.2010.06.251 Smith, 2006, Signal Switching, Crosstalk, and Arrestin Scaffolds: Novel G Protein–Coupled Receptor Signaling in Cardiovascular Disease, Hypertension, 48, 173, 10.1161/01.HYP.0000232641.84521.92 Kolch, 2000, Meaningful Relationships: The Regulation of the Ras/Raf/MEK/ERK Pathway by Protein Interactions, Biochem. J., 351, 289, 10.1042/bj3510289 Lin, 2013, Beta-Arrestin-Kinase Scaffolds: Turn Them On or Turn Them Off?, Wires. Syst. Biol. Med., 5, 231, 10.1002/wsbm.1203 Peters, 2010, Comparing Label-Free Biosensors for Pharmacological Screening with Cell-Based Functional Assays, Assay Drug Dev. Technol., 8, 219, 10.1089/adt.2009.0232 Bilski, 1983, The Pharmacology of a Beta 2–Selective Adrenoceptor Antagonist (ICI 118,551), J. Cardiovasc. Pharmacol., 5, 430, 10.1097/00005344-198305000-00013 Schall, 1990, Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor, Cell, 61, 361, 10.1016/0092-8674(90)90816-W Canton, 1990, Binding of Typical and Atypical Antipsychotics to 5-HT1C and 5-HT2 Sites: Clozapine Potently Interacts with 5-HT1C Sites, Eur. J. Pharmacol., 191, 93, 10.1016/0014-2999(90)94100-C Matsumoto, 1995, Characterization of Two Novel Sigma Receptor Ligands: Antidystonic Effects in Rats Suggest Sigma Receptor Antagonism, Eur. J. Pharmacol., 280, 301, 10.1016/0014-2999(95)00208-3 McGuinness, 2009, Enhanced Selectivity Screening of GPCR Ligands Using a Label-Free Cell Based Assay Technology, Comb. Chem. High T. Scr., 12, 812 Miyatake, 2009, Inhibition of EGF-Induced ERK/MAP Kinase–Mediated Astrocyte Proliferation by Mu Opioids: Integration of G Protein and Beta-Arrestin 2–Dependent Pathways, J. Neurochem., 110, 662, 10.1111/j.1471-4159.2009.06156.x Aggarwal, 2003, Signaling Pathways of the TNF Superfamily: A Double-Edged Sword, Nat. Rev. Immunol., 3, 745, 10.1038/nri1184 Han, 2014, Additive effects of EGF and IL-1beta Regulate Tumor Cell Migration and Invasion in Gastric Adenocarcinoma via Activation of ERK1/2, Int. J. Oncol., 45, 291, 10.3892/ijo.2014.2401 Song, 2009, How Does Arrestin Assemble MAPKs into a Signaling Complex?, J. Biol. Chem., 284, 685, 10.1074/jbc.M806124200 Delcourt, 2007, GPCR-Jacking: From a New Route in RTK Signalling to a New Concept in GPCR Activation, Trends Pharmacol. Sci., 28, 602, 10.1016/j.tips.2007.09.007 Luttrell, 2001, Activation and Targeting of Extracellular Signal–Regulated Kinases by Beta-Arrestin Scaffolds, Proc. Natl. Acad. Sci. U. S. A., 98, 2449, 10.1073/pnas.041604898 Leister, 2011, Two High Throughput Screen Assays for Measurement of TNF-alpha in THP-1 Cells, Curr. Chem. Genomics., 5, 21, 10.2174/1875397301105010021